Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26517033 | 0.81 | NOTUM (0.49) | KDM4ENOTUMMEN1KMT2AALDH1A1 | |
| SCHEMBL23917418 | 0.80 | NOTUM (0.43) | KDM4ENOTUMAADATMEN1KMT2A | |
| SCHEMBL13345024 | 0.77 | KDM4E (0.83) | KDM4ENOTUMMEN1KMT2AALDH1A1 | |
| SCHEMBL21172818 | 0.72 | AADAT (0.43) | KDM4ENOTUMAADATALDH1A1MAPT | |
| SCHEMBL21172770 | 0.72 | NOTUM (0.62) | NOTUMALDH1A1LMNAPOLB | |
| SCHEMBL26079156 | 0.69 | NOTUM (0.64) | KDM4ENOTUMMEN1KMT2AMAPT | |
| SCHEMBL21172928 | 0.69 | HPGD (0.55) | KDM4ENOTUMALDH1A1MAPTTP53 | |
| SCHEMBL21172863 | 0.69 | HSD17B3 (0.50) | KDM4ENOTUMMEN1KMT2AALDH1A1 | |
| SCHEMBL24347198 | 0.69 | HPGD (0.55) | KDM4ENOTUMALDH1A1MAPTTP53 | |
| SCHEMBL21172600 | 0.69 | NOTUM (0.60) | NOTUMMEN1KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | KDM4E 1755/4885NOTUM 2740/4885AADAT 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.